Podcasts about Fana

Join Dr. Olga Kagan, founder of the Food Allergy Nursing Association (FANA), as she shares insights on revolutionizing food allergy care through nursing innovation, technology, and evidence-based practice. Learn how FANA is empowering nurses to lead transformative change in this critical healthcare subspecialty while improving patient outcomes and quality of life.Discover how nursing leadership is revolutionizing food allergy care through evidence-based practiceLearn strategies for implementing innovative, technology-driven care models in specialty nursingUnderstand the impact of nurse-led research and education on patient outcomes in food allergy managementOlga Kagan, PhD, RN, CIMI, FHIMS, Founder, Food Allergy Nursing Association (FANA)Megan Antonelli, Chief Executive Officer, HealthIMPACT Live

Card Talk with Mrs. Doc April 2nd, 2025 brings Bowman Chrome University Basketball, Panini Select Baseball, Vintage Onyx, and Topps Inception Football!

Alt om seriestart frå Norsk Tipping-ligaen og opp. 1. omgang: Osingar i eksil, toppfotball og temperament. 2. omgang: Norsk Tipping-ligaen med Fana-trenar Ørjan Håland som gjest. Programleiar: Davy Wathne. Fotballekspert: Lars BakkerudFor å høre hele episoden må du ha abonnement, det skaffer du deg herEr du abonnent får du tilgang til medlemsfeeden herSleivkast er sponsa av 2Stabilise – eit oljeservicefirma frå Os som produsererpolyuretanfôringar i Nordsjøen – og som bruker den same patenterte blandinga til å bygga solide, fleksible og miljøvenlege fenderar til kaiar og bryggeanlegg. Les meir på 2stabilise.com Hosted on Acast. See acast.com/privacy for more information.

Panelet sliper knivene før slaget i Fana. Calle sikter mot sub 2.45 og håper på bra felt. Mathias sliter med jobbtur dagen før løpet. Martin har tatt på seg lokfører-hatten til helgens batalje! Eggen Mjøs og og Øyvind Macody ender opp i en grusom gjørmebryting om lokale løyper.

250323 GLOBALSunday Freedom From The Known

Panelet oppsummerer den siste tids trening. Den neste ukes trening og nøkkeløkter blir et hett tema, og Kristian Ulriksen kommer med sine synspunkter på de siste detaljene. Øyvind  kommer med et skikkelig knyttneveslag som sender hele panelet rett i canvasen. Han stiller spørsmålstegn ved mentaliteten og innstillingen til maratongruppen. 

Innovating Food Allergy Care: How Nursing Leadership and Technology Are Transforming Patient Outcomes Join Dr. Olga Kagan, founder of the Food Allergy Nursing Association (FANA), as she shares insights on revolutionizing food allergy care through nursing innovation, technology, and evidence-based practice. Learn how FANA is empowering nurses to lead transformative change in this critical healthcare subspecialty while improving patient outcomes and quality of life. • Discover how nursing leadership is revolutionizing food allergy care through evidence-based practice • Learn strategies for implementing innovative, technology-driven care models in specialty nursing • Understand the impact of nurse-led research and education on patient outcomes in food allergy management To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Har fått tidenes mest herlige og udugelige hund som spiser oss ut av det meste. Usikker på om han har noen som helst tanker utenom å tygge og spise på alt. Men at det finnes mennesker som ikke hører sine egne tanker, er blitt evig fascinerende og blir mer og mer fokusert på. Så snakker om det, om det elendige språket vi alle kan, engelsk. Om hvor tullete mange kinesere og indere det er. Tungeknekkere. Bittelitt Musk. Og litt annet!Mitt nye show “Tenker Tanker” er ute for salg nå! https://www.ticketmaster.no/artist/christoffer-schjelderup-billetter/983426Billetter til Showet på 5071 i Loddefjord 28. mars kommer snart...Ekstrashow med Jan Tore Kristoffersen der vi tester stoff 2. april i Fana: https://www.ticketmaster.no/event/christoffer-schjeldrup-og-jan-tore-kristoffersen-tester-stoff-tickets/234377091Se hele Specialen "Tro, Hat & Ærlighet" her https://youtu.be/bXPbyBUK3HAFølg meg på facebook: https://www.facebook.com/standupchristofferTwitter: https://twitter.com/CSchjelderupInstagram: https://www.instagram.com/christofferschjelderupTikTok: https://www.tiktok.com/@christofferschjelderup Hosted on Acast. See acast.com/privacy for more information.

Lekte dere "Kyss, Klapp og Klem" på barneskolen og hva f--n var klappet? Er det en internasjonal greie?! Og hva er dine tanker om Luigi Mangione og er han bedre eller verre enn broren til Mario? Det fjases over en lav sko og det kommer snarlig to bonusepisoder på Patreon, så hiv deg gjerne med der.Og kom deg på show! Skal være med på Varmere Våtere Villere-festivalen i Bergen i morgen(fredag den FJORTENDE!!! mars) på Rebel https://ticketco.events/no/nb?pattern=apokalypsen%C3%A5vvvSkal også stikke innom å gjøre et sett på klubbkvelden til Standupbergen https://www.ticketmaster.no/event/klubbkveld-med-stand-up-bergen-tickets/2028756499?language=en-usJeg og Jan Tore skal teste stoff i Fana onsdag 2. april og har satt opp ekstrashow 18:00 - https://www.ticketmaster.no/event/christoffer-schjeldrup-og-jan-tore-kristoffersen-tester-stoff-tickets/234377091Doug Stanhope kommer på Forum Scene og jeg skal varme opp: https://www.ticketmaster.no/event/doug-stanhope-out-of-hibernation-tickets/1480973877?language=en-usMitt nye show “Tenker Tanker” er ute for salg nå! https://www.ticketmaster.no/artist/christoffer-schjelderup-billetter/983426Bli endel av min Patreon her: https://www.patreon.com/skamfrelst Hosted on Acast. See acast.com/privacy for more information.

Hace 50 años que se grabó en Johannesburgo este disco del grupo sudafricano Themba ahora reeditado y del que suenan los cortes 'Themba themba' y 'Fana fana'. Del disco brasileño de la pianista canadiense Rosnes, 'Crossing paths', 'Pra dizer adeus' de Edu Lobo -con la voz del propio Edu-, 'Essa mulher' de Joyce Moreno y Ana Terra -con la voz de Joyce-, 'Trilhos urbano' de Caetano Veloso y 'Amor até o fim' de Gilberto Gil. Y Kurt Elling, el cantante de Chicago, acompañado por el pianista Sullivan Fortner en 'Ana Maria', de Wayne Shorter, y por el pianista Joey Calderazzo en 'Lost in the stars' de Kurt Weill y Maxwell Anderson y 'Stars (Endless stars)' de Fred Hersch y Norma Winstone. Abren la sesión Carlos Malta y Pife Muderno con 'Lero lero' de su disco 'Edu pife' dedicado a Edu Lobo.Escuchar audio

Kjenner du til Streisand-effekten? For nå har vi en historisk mulighet til å fornorske det uttrykket, og hvis du ikke aner hva jeg snakker om så anbefaler jeg voldelig å få med deg siste episode av den ikke i nærheten av prisvinnende podcasten Skamfrelst - norges første humorpodcast fra en av norges mest utrente komikere. Og hvis du vet hva jeg snakker om så anbefales den enda mer!Og hvis du vil på show med Jan Tore og meg i Fana så finner du billetter her: https://www.ticketmaster.no/event/christoffer-schjeldrup-og-jan-tore-kristoffersen-tester-stoff-billetter/1662416664Mitt nye show “Tenker Tanker” er ute for salg nå! https://www.ticketmaster.no/artist/christoffer-schjelderup-billetter/983426Se hele Specialen "Tro, Hat & Ærlighet" her https://youtu.be/bXPbyBUK3HABli endel av min Patreon her: https://www.patreon.com/skamfrelstFølg meg på facebook: https://www.facebook.com/standupchristofferTwitter: https://twitter.com/CSchjelderupInstagram: https://www.instagram.com/christofferschjelderupTikTok: https://www.tiktok.com/@christofferschjelderup Hosted on Acast. See acast.com/privacy for more information.

Oscaren har vært, og Norge fikk sin andre statuett. Kunne blitt mer, men tidligere Hotel Cæsar-skuespiller Mona Fastvold og ektemannen tapte på målstreken for Sean Baker, som tok en Walt Disney og vant fire oscars på en kveld. Gal Gadot kom også litt i fokus, og jeg snakker om det og snøhvit og har masse betraktninger på hollywoodfilmens store aften!Billetter til JTK og meg som tester stoff i Fana: https://www.ticketmaster.no/event/christoffer-schjeldrup-og-jan-tore-kristoffersen-tester-stoff-tickets/1662416664 Hosted on Acast. See acast.com/privacy for more information.

參考書目：《你知道的太多了》，作者：施宇宸 這集我們會談到： 1.行政執行署對於欠稅大戶有什麼「大絕招」呢？ 2.和解之後就萬無一失了嗎？為何賠錢了還是被告？ 3.如何避免和解後再被提刑事告訴？須完成哪些事項？ 4.簽署和解書該注意哪些事情才能避免後續爭議？ 5.線上遊戲盜寶或盜帳號有罪！怎樣會觸犯妨害電腦使用罪？ 6.偷看孩子手機可能觸犯妨害秘密罪？哪些情況下可看？ 7.往生者的手機如何解碼？蘋果公司的相關規定為何？ 8.Anna表弟往生後手機密碼無法被破解，最終如何處理？ 9.討論：該不該看往生者的手機？Joe&Fana激烈辯論 【背景介紹】 《你知道的太多了》是一本超好笑又帶點腹黑的法律攻防經典，書中以輕鬆詼諧語調來介紹日常生活中會遇到的各種情境法律知識，內容淺顯易懂，可以讓一般民眾藉由此書了解該如何保護自己的權益….。 請贊助我一杯咖啡，感謝您的贊助，讓我們能走得更遠、更久

A fluffy episode to chase away some of the blues, whether it be just winter griping or something more serious. Take care of each other and stay safe, everyone! Tune in to hear Ash reconnect with his Snorlax over another Snorlax, some great wordplay and not so gret wordplay, and a tale of people and pokemon working together!

參考書目：《你知道的太多了》，作者：施宇宸 這集我們會談到： 1.法律的處罰牽扯到哪三種法律？其項目分別為何？ 2.「一過不二罰」，此一概念合理嗎？實際情況如何？ 3.案例一：Joe年輕時遇到家長的何種質疑？後續如何發展？ 4.如何分辨刑事與民事案件？告輸了分別會如何呢？ 5.可以同時提告刑事與民事嗎？怎樣提告比較「省錢」？ 6.刑事與民事案件的提告流程、地點、偵辦有哪些差異？ 7.案例二：Anna提告「偽造公文書罪」的經驗為何？ 8.案例三：Fana特教實習時遇到何種「不舒服」的狀況？ 9.教師職場可能遇到怎樣各式各樣的「性騷擾」問題？ 【背景介紹】 《你知道的太多了》是一本超好笑又帶點腹黑的法律攻防經典，書中以輕鬆詼諧語調來介紹日常生活中會遇到的各種情境法律知識，內容淺顯易懂，可以讓一般民眾藉由此書了解該如何保護自己的權益….。 請贊助我一杯咖啡，感謝您的贊助，讓我們能走得更遠、更久

Pour la 100ème de Jumpseat, Fred Marsaly reçoit Xavier Méal et Rémy Michelin des photographes aéro de talent pour parler de leur expérience et de leurs parcours, de leurs photos marquantes, qu'elles soient réussies ou ratées !On remercie le Fana de nous avoir accueilli dans leurs locaux : https://boutiquelariviere.fr/magazine/aviation-et-modelisme/fana-de-l-aviation/00:00 Intro00:01:09 Rémy Michelin, photographe aéronautique00:02:33 La naissance d'une passion00:09:54 Xavier Méal, journaliste et photographe aéronautique00:13:40 Apprendre le métier en agence par Rémy Michelin00:15:50 les grenouilles de Roland Garros00:18:44 la claque "De Plumes et de Fer" 00:23:23 Xavier Méal et ses "Avions de Rêve" 00:28:42 L'importance du « matos » photo00:32:04 Canon ou Nikon ?00:35:43 « Air to Air » avec 4 avions de la Sécurité Civile par Rémy Michelin00:38:48 Les avions utilisés pour les vols photo00:41:02 Rémy Michelin en vol et face à la Patrouille de France 00:49:21 Me 262, MiG-15 et F-86, le trio de Melun par Xavier Méal00:51:47 Organisation d'un vol photo, l'importance de la préparation.00:58:49 6 DC-3 devant mon objectif par Xavier Méal01:05:05 Rémy Michelin : les risques du métier ou comment je me suis fait doucher par un Canadair !01:13:40 Le Rafale Solo Display, une histoire d'amitié par Rémy Michelin01:18:20 Se lancer dans le métier aujourd'hui01:22:11 photographier deux Mirage 2000 à Djibouti 01:24:11 Le noir et blanc à l'heure du numérique, un choix d'artiste(s)01:25:10 "photographier au 1200mm !" 01:29:30 « Ondes de choc », tir canon en Mirage 2000 par Rémy Michelin01:31:20 un presque raté, La P.A.F au-dessus de Carcassonne01:38:28 Un DC-3 sur la dune du Pilat par Xavier Méal01:39:47 Patrouille mixte, P-51 Mustang et Rafale Marine01:42:28 Météo changeante : Les Mirage 2000 de la patrouille « Gusto » 01:43:34 « Carlingues », le nouveau livre de Rémy Michelin01:46:10 avions de rêves et d'exception par Xavier MéalRetrouvez #Jumpseat tous les mardis midi en direct sur #twitch :https://www.twitch.tv/jumpseat_abz-----Retrouvez-nous :Sur https://aerobuzz.frSur Twitch : https://www.twitch.tv/jumpseat_abzSur Tiktok : https://www.tiktok.com/@jumpseat_abzSur Twitter : https://twitter.com/AeroBuzzfrSur Instagram : https://www.instagram.com/jumpseat_abz/Sur Facebook : https://www.facebook.com/Aerobuzz.frHébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

這集我們會談到： 1.Fana去拔智齒了，不拔智齒可能帶來何種影響？ 2.什麼時候是拔智齒的最好時間？太早、太晚都不好？ 3.怕痛的新選擇，舒眠拔牙價格大概多少？划算嗎？ 4.小朋友的牙齒該怎麼顧？Alana2-3歲蛀牙縫血淚史！ 5.補牙縫為何需自費？不同的牙醫診所大不同？？ 6.不怕牙醫的小孩很勇敢？兒童牙醫的話術都一樣？ 7.閒聊1：男女怕痛感受大不同，Anna按摩吃重鹹？？ 8.閒聊2：舒眠麻醉有其危險性，做治療前該注意什麼？ 9.閒聊3：Joe的無痛大腸鏡&Anna沒打無痛的生產經驗 10.自然產&剖腹產的差異為何？為何選擇自然產？ 11.閒聊4：全台最高生產補助—苗栗縣通霄鎮 12.當前生孩子能擁有哪些相關補助或津貼？？ 【背景介紹】 智齒，又稱為第三大臼齒，是人類口腔內最晚萌出的牙齒，智齒的生長情況因人而異，通常智齒會在16至25歲之間萌發。每個人的口腔狀況不同，智齒的生長若影響其他牙齒的移動、難以清潔導致發炎、生長時對原本牙齒擠壓而導致不整齊，都是選擇拔智齒的主要原因….。 請贊助我一杯咖啡，感謝您的贊助，讓我們能走得更遠、更久

Stalker 2: Heart of Chornobyl to jedna z głośniejszych premier zeszłego roku. Gra nie tylko była wyczekiwana przez wielu graczy na świecie, ale już zapisała się w historii jako dzieło ukraińskiej kultury, tworzone w trakcie trwającej w tym kraju wojny. Nic dziwnego, że tytuł ten budzi wiele emocji, nie tylko u naszych sąsiadów. W tym odcinku Jusek opisuje swoje dotychczasowe wrażenia ze Stalkera 2 okiem wieloletniego fana serii. Porównuje go z poprzednimi częściami (było ich kilka, acz bez numeracji) i znanymi fanowskimi modyfikacjami, ocenia nowości, krytykuje braki oraz zastanawia się...Przeczytaj całość

"Un sancerre de Bourgogne SVP". C'est ce qu'on appelle en sommellerie "un briseur de rêves", à savoir un client de grande table qui, sûr de lui, étale au grand jour son ignorance.Pour aborder ce thème et pour bien démarrer cette année 2025, Paul-Louis Coudoumié, sommelier que j'avais déjà reçu dans 20 Divin en 2022 (épisode #35 sur le marché Gris), et créateur de carte de vins pour des tables étoilées, m'a invité à déguster les plats concoctés par ses amis, le chef  Gabriel Gras Fernandez et le chef pâtissier Jorice Sardain dans leur restaurant parisien «Fana».Gabriel, formé chez Michel Sarran, Jean-Pierre Vigato et Christain Le Squer, et Jorice, qui a travaillé chez Nicolas Bernardé puis Cédric Grolet au Meurice, se sont rencontrés au Bistrot du 11 à Versailles avant de créer « Fana », ouvert en mai dernier dans le 18ème à Paris.A travers trois belles cuvées sélectionnées par Paul-Louis, nous allons découvrir les plats signature de ce restaurant convivial et revenir sur ces briseurs de rêve, qui ont jalonné le parcours de ces 3 compères.Bonne dégustation

Anti-amyloid therapies provide the first FDA-approved option to alter AD pathology, but an understanding of overall utility and value to patients remains in its infancy. In this episode, Teshamae Monteith, MD, FAAN, speaks with David S. Geldmacher, MD, FACP, FANA, author of the article “Treatment of Alzheimer Disease” in the Continuum® December 2024 Dementia issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Geldmacher is a professor and Warren Family Endowed Chair in Neurology and the director of the Division of Cognitive and Behavioral Neurology, Department of Neurology, Marnix E. Heersink School of Medicine at the University of Alabama at Birmingham in Birmingham, Alabama. Additional Resources Read the article: Treatment of Alzheimer Disease Subscribe to Continuum: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Transcript Full interview transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum, the premier topic-based neurology clinical review and CME journal from the American Academy of Neurology. Thank you for joining us on Continuum Audio, which features conversations with Continuum's guest editors and authors who are the leading experts in their fields. Subscribers to the Continuum journal can read the full article or listen to verbatim recordings of the article and have access to exclusive interviews not featured on the podcast. Please visit the link in the episode notes for more information on the article, subscribing to the journal, and how to get CME. Dr Monteith: This is Dr Teshamae Monteith. Today, I'm interviewing Dr David Geldmacher about his article on treatment of Alzheimer's disease, which appears in the December 2024 Continuum issue on dementia. Welcome to our podcast, Dr Geldmacher. How are you?  Dr Geldmacher: I'm very well, thank you. It's a pleasure to be here.  Dr Monteith: Yeah. So, why don't you introduce yourself to our audience? Dr Geldmacher: Sure. I'm David Geldmacher. I'm a professor of neurology at the University of Alabama in Birmingham and I lead the division of Cognitive and Behavioral Neurology.  Dr Monteith: So, I'm really excited about this, to personally learn, and I know that or neurology community is also really excited about this interview. So, why don't we start off with your main objective.  Dr Geldmacher: So, my main goal in the article was to review the FDA-approved pharmacologic treatments for dementia. There's lots of ways of thinking about treatment of dementia; psychosocial, caregiver support, and so forth. But I really wanted to focus on the issues of drug treatment because that's what has been our backbone for a long time and now has recently expanded.  Dr Monteith: Why don't we talk a little bit about, first of all, the boom in the field? What's that been like?  Dr Geldmacher: So, the big change in the field is over the last several years, we've had treatments become available that actually attack the underlying Alzheimer pathology, and that's new and different. For decades, we've been able to treat the symptoms of the disease, but this is the first time we've really been able to get to the root of the pathology and look toward removing amyloid plaques from the brain.  Dr Monteith: Let's step back a little bit and talk about the framework of diagnosis and how that leads into the therapeutic potential. I know you're going to dive into some of the biologics, but we should probably talk about the kind of holistic approach to considering the diagnosis. Dr Geldmacher: Sure. So, you know, when someone comes to the clinic with memory complaints, our question we have to ask is, is this neurologic origin, a structural origin like Alzheimer's disease or vascular dementia? Are there complicating factors, the software issues of mood disorders and sleep disorders and pain that can all magnify those symptoms? The clinical reasoning is a critical part of that, but in Alzheimer's disease, typically the problems revolve around difficulty forming new memories of events and activities, the episodic memory. And then it's often accompanied by changes in word finding and semantic knowledge. And those are the things that we look for in the clinic to really point toward an AD diagnosis. And then we support it with exclusion of other causes through blood work and identification of patterns of brain atrophy on MRI. And then most recently in the last couple of years, we've been able to add to that molecular imaging for amyloid with PET scans as well as, most recently, blood-based biomarkers for Alzheimer's pathology. So, it's really been a revolution in the diagnosis over these last several years.  Dr Monteith: And when approaching patients or populations of individuals, there seems to be a real full spectrum with looking at the societal burden, the biological impact, of course, risk factors of primary prevention, and now this whole area of brain health and secondary prevention. How do you kind of tie all of this together when talking to patients and family members?  Dr Geldmacher: Sure. So, the approaches for brain health apply to everyone. In basically every clinic visited, our brain aging and memory clinic, we reviewed lifestyle approaches to brain health like regular physical exercise, healthy diet, cognitive and social stimulation. And those are fundamental to the approach to everyone, whether they have cognitive impairments that are measurable or not. These are all things that are good for our brain health. And then, you know, focusing on the vascular risk factors in particular and working with the patient and their primary care team to ensure that lipids and blood sugar and blood pressure are all in good healthy ranges and being appropriately treated.  Dr Monteith: You know, there's this kind of whole considerations of clinically meaningful endpoints and clinical trials, and even when we're talking to our patients. What would you say the field has kind of identified has the best endpoints in helping patients? Would you call it impaired daily function? Is that like the best hard endpoint? Obviously, there are other things such as caregiver burden, but you know, how do you approach assessing patients? Dr Geldmacher: Defining the endpoints is very difficult. Typically, if we talk to patients and their families, they would like to have better memory or improve memory. How that applies in everyday life actually is daily function. And so, we focus very much on daily function. And when I talk about our therapies, whether they're symptomatic therapies or the new disease-modifying therapies, I really talk about maintenance of function and delays and decline or slowing of decline, helping to foster the person's independence in the activities that they have and be able to sustain that over the longer term.  Dr Monteith: And when thinking about diagnosis- and we're going to get into treatments, but when thinking about the diagnosis, and of course, it's full-spectrum from mild cognitive impairment to moderate and severe forms of dementia, but who should have CSF testing and PET imaging? Obviously, these are invasive, somewhat invasive and expensive tests. Should all people that walk in the door that have memory complaints? How do you stratify who should have tests? Dr Geldmacher: I think about this in a big funnel, basically, and the starting point of the funnel, of course, is the person with memory complaints. Then there's that neurologic reasoning. Are these memory complaints consistent with what we expect from the anatomy of Alzheimer's disease, with atrophy in in the hippocampus and temporal lobe? Do they have episodic memory loss or not? That first step is really trying to characterize, do the clinical patterns act like those of Alzheimer's disease or not? And then we follow the Academy of Neurology guidelines, looking for reversible sources of cognitive decline, things like B12 deficiency and depression, sleep disorders and the like, and try to exclude those. We start with structural imaging with everyone, and MRI, typically, that will help us understand vascular burden and patterns of atrophy, looking for things like mesial temporal atrophy or precuneus atrophy that are characteristic of Alzheimer's disease. If those things are all pointing in the direction of AD as opposed to something else, then typically before moving on to CSF or PET scan, we will use blood-based biomarkers, which are one of the big changes in the field in the last year or so, and there are now multiple panels of these available. The downside is they are typically not covered by insurance. On the other hand, they can really help us identify who is likely to have a positive PET scan or positive findings on CSF. We start to provide that counseling and information to the patient before they get to those more definitive tests. We can push people in the other direction. We can say, your blood-based biomarkers are negative or do not indicate AD as the most likely source of your condition now, so let's treat other things. Let's see what else we can focus on. The blood-based biomarkers are now, in our clinic at least, the critical choke point between the routine workout that we've always done on everyone and then the more advanced workup of proving amyloid pathology with CSF or a PET scan. Dr Monteith: How sensitive are those blood biomarkers and how early are they positive?  Dr Geldmacher: The sensitivity is generally pretty good, in the ninety plus percent range on average and it depends on which panel. And as you point out, when in the course of symptoms that they're done, we know that they become positive and presymptomatic or asymptomatic people. We're using these kinds of markers to screen people for prevention trials. So, I think when someone is symptomatic, they're a good indicator of the presence or absence of AD pathology. Now that doesn't mean the AD pathology is the sole cause of their symptoms. And so, we still need to think about those other things like sleep and mood and so forth. But they do point us in the in the direction of Alzheimer's change.  Dr Monteith: So why don't we talk about some of the more standard older treatments, and it's also important to leave with kind of some rational approach to when we start and what should we be counseling our patients on. So why don't we start with the older, you know, choline esterase inhibitors and then some of the MDA- I guess there's only one modulator, SEPTA modulator. Dr Geldmacher: So, I've been really fortunate in my career span, the time from the first of those symptomatic agents reaching the market in 1993 to seeing the disease modifying drugs enter the market now. I think most neurologists actually have entered practice after those clinical trials of the colon esterase inhibitors were published. So, one of my goals in this article was to review that primary data and what can we expect from those symptomatic drugs. We know that they are inconsistently effective in mild cognitive impairment, and the Academy of Neurology guidelines says there is not strong evidence to use them in mild cognitive impairment. But in mild AD and beyond, the cholinesterase inhibitors provide meaningful benefits. They delay decline, they can delay nursing home placement. They reduce overall costs of care. So, I think they provide real value. So, in the article I have reviewed what the data looked like on those. My approach is to start with oral Donepezil at five milligrams and increase it to ten in everyone who tolerates the five. If for whatever reason the oral Donepezil is not well tolerated, I'll switch to transdermal rivastigmine to help improve tolerability. There are very few head to head comparisons, but nothing suggests that one of the cholinesterase inhibitors is superior to the other for clinical outcomes, and there's no evidence to support conjoint use of more than one at a time. Should someone be showing decline then on typical cholinesterase inhibitor therapy - and people will, it's often delayed, but the decline will reemerge - then I will add the NMDA receptor, a modulator memantine and titrate that up to full dosing, either 10 mg twice a day for the conventional release or 22 mg extended release. And at that point we're sort of on maximal pharmacologic therapy for Alzheimer's disease. These agents can provide some benefit in other conditions, they're off-label except for Lewy body disease where rivastigmine is labeled. But they can provide benefit across different conditions. And there's some preliminary data, for instance, of acetylcholinesterase inhibitors being helpful in vascular cognitive impairment. So, I will use them, but I expect the greatest response when someone really does follow the patterns of Alzheimer's disease.  Dr Monteith: And you have a great chart, by the way, and nice figures looking at some of the meta-analyses on cognitive outcomes as well as functional outcomes. So, thank you for that.  Dr Geldmacher: In general, all of those tables favor treatment over placebo in the domains of cognition, daily function, neuropsychiatric symptoms. And it's that consistency of result that lets me know that we really are seeing a drug effect, that it's not a class effect with those, that we really are helping our patients. It's not like some studies are positive and some are negative. They are very consistently positive. Small magnitude, but consistently positive.  Dr Monteith: And I know we have a lot of patients coming in where, at least, their caregivers are complaining about agitation, and sleep is also a problem for others. And so how do you help that patient? I know you have a good algorithm that also you included in your article, but why don't you summarize how we should approach these symptoms? Dr Geldmacher: Sure. So, for nonpsychotic agitation, you know, just restlessness, wandering, pacing and so forth, my first choice is an off-label use of citalopram. And there is good clinical trials evidence to support that. if someone has psychotic agitation that is with delusions or hallucinations and so forth, I think we do need to move to the antipsychotic drugs. And the one drug that is now approved for treatment of agitation and Alzheimer's disease does fall into that antipsychotic category, along with its various black box warnings - and that's brexpiprazole. For many of our patients, getting coverage for that agent is difficult. It's not on many formularies. So, it is something I progress toward rather than start with. Similarly, for sleep, there is one approved agent for sleep, that's a dual orexin agonist. And it shows effectiveness, but can have some negative cognitive effects, and so I tend not to start with that either. My first choice when sleep is the primary issue for our patients with dementia is trazodone, and there are some small, limited studies for it's off-label used to enhance sleep. It's safe, inexpensive, often effective, and therefore it's my first choice. Dr Monteith: So, now let's get into the big conversations that everyone is having. Let's talk about the newer disease modifying anti amyloid therapies. Give us a summary dating back 2021 probably, although we can hold the preclinical work, but let's talk about what is available to our patients. Dr Geldmacher: Sure. And the development of anti-amyloid therapies goes all the way back to 1999. So, it's a pretty long course to get us to where we are today.  Dr Monteith: Yeah, that's why we limited that.  Dr Geldmacher: With that first approved agent with aducanumab in 2021, it received a limited or accelerated approval in FDA parlance. These agents, the aducanumab, lecanemab and donanemab, all approved, are known to remove amyloid pathology from the brain as measured by CSF and/or BIPET. They are amyloid lowering therapies, often called disease-modifying therapies. And across the agents there's some variable results. But if we look at the two with full approval, lecanemab and donanemab, they slow clinical progression by 25% to 35% on average. And that's measured by either cognitive measures or global measures or composite measures, but it's pretty consistent in that range of about one-third slowing. That makes it really difficult to discern in an individual patient, though, because there's so much variability in the progression of the disease already that it can be difficult to tell in one person that these drugs are working. They're also complex to use, so there's a qualification process that involves MRI to exclude things like a high tendency toward hemorrhage. It includes genetic testing for papal E4 status to help us understand the risk for complication, and then once-monthly or twice-monthly infusions with standardized schedule for MRI scanning. So, there's a lot that goes into managing these agents. And they are expensive, and we don't yet know their cost effectiveness. The cost effectiveness of the cholinesterase inhibitors was questioned when they first came out back in the 1990s, and it took five or ten years to really understand that they provided benefit to society and to individuals in those domains of quality of life and return on investment. And we're still learning about that with the disease modifying therapies.  Dr Monteith: So, two questions. One, the case that you presented was an individual having symptoms and kind of voiced their desire to be on these therapies. So, people are going to be asking, coming to clinic asking and then of course, they're going to be people that you select out. So, how do you make that decision to recommend this treatment for patients given the potential risk? Dr Geldmacher: We've got some really good guidance from appropriate use recommendation papers for aducanumab and lecanemab, and I'm expecting one from donanemab fairly soon. But the key is to identify individualized risks, and that involves knowing their APOE4 status, knowing their- whether they've had microhemorrhages in the brain previously, and then documenting that they really do have amyloid pathology with something like PET scan to establish those baselines. I talk to people about the burden of twice-monthly infusions or, now with donanemab, once-monthly infusions. And for instance, for someone who's got a working caregiver, getting to an infusion center twice a month can be a significant burden. And then if there are complications, frequent MRI scans and so forth. So, we talk about the burden of entering into this therapeutic pathway. The reality is that people who are qualified generally want it. I have relatively few folks who have said, no, these risks are more than I'm willing to accept. For decades my patients have said, anything you can do to slow this down, I'm willing to try. And now we're seeing that translated to reality with people willing to accept high-risk, high-cost treatments with the chance of slowing their individual progression.  Dr Monteith: And how do you select between the two treatments? Dr Geldmacher: So far that's been easy because donanemab's not readily available.  Dr Monteith: Outside of clinical trials, right?  Dr Geldmacher: Exactly. For prescription use, it's coming in - the first cases have now been infused - but it's not generally available. Nonetheless, what I will do for patients in this is look at the risk tables. So donanemab appears to have in general some higher rates of the Aria complications, amyloid-related imaging anomalies, and some people are going to be more risk tolerant of that for the payoff of potentially faster response. The donanemab trials restructured that. They did their first assessment of effectiveness. I had amyloid removal at six months and a significant proportion of people were eligible to discontinue treatment at six months because their amyloid was below treatable thresholds. So higher risk, perhaps faster action and fewer infusions for donanemab. Lecanemab we have more direct experience with, and between the two of them, the eighteen month outcomes are pretty much the same and indistinguishable. So are we in it for a quick hit, or are we in it for the long race? And different patients and different families will have differing opinions on where they want to accept that risk and burden and so forth. But so far, the data don't indicate a lot of difference in their longer-term outcomes. We still have plenty to learn.  Dr Monteith: And so, it sounds like, as you mentioned, we're looking at eighteen months out for kind of a hard outcome, and that there is a lot of variability in response rate. How are you tracking patients- you know about the imaging, so just in terms of clinical outcomes and efficacy?  Dr Geldmacher: Sure. So, for Medicare to reimburse on these treatments, people need to be enrolled in a registry program - and there are several of these, CMS runs one of their own. But the requirement for that is, every six months, to do cognitive and functional outcomes through the first two years. Cognitive outcomes are up to the clinician, but things like the mini mental state exam, the MoCA, are appropriate. In our own program, we use something we developed locally called the Alabama Brief Cognitive Screener. As for the cognitive outcomes and then for functional, we use an instrument called the General Activities of Daily Living Scale, but there are many other ADL scales that could be used as well. CMS does not mandate specific tests. Since the progression of the disease is variable to begin with, we don't really know how to interpret these results in reference to whether the drug is working, but I can tell a patient or a family member, your scores are stable, or, you have a decline of three points in this test. That's typical for this duration of illness. But there isn't a good way to know whether the drug is working in this person at this time, at least with our current levels of data.  Dr Monteith: So, I think we have to talk about health equity, and it sounds like Medicare is reimbursing for some of us. We look at different socioeconomic backgrounds, educational backgrounds, race, ethnicity. Not everyone is aware of these treatments. So, how do we get more patients to become aware of these treatments? And how do we get them to more people to help people? Dr Geldmacher: Yeah, I mean, that's- it's a major, major issue of inequity in our population. We've done some work at UAB looking at the flow of members of minority communities into memory clinics. So, we know that the overall population of, and I'll choose, for an example, blacks and African Americans, that they are represented a much higher rate in our overall UAB treatment population than they are in our memory clinic population. So, they're not even getting to us in the specialty clinic at the same rates as other segments of our population. We also know that blacks and African Americans in our population are not receiving PET scans as often as the overall treatment population. So yes, there are real, real problems with access. There are cultural issues behind this as well. And in many communities, a change in cognition, a loss of memory is an expected part of the aging process rather than recognized as a disease. So, people who come to us from minority communities are often further along in the course of cognitive and functional decline and beyond the point where they might qualify for the disease-modifying therapies, where early AD is the sort of defining boundary. So, I think more awareness and more screening in primary care settings, perhaps more community outreach to let people know that changes in memory that affect daily function are not normal as part of the aging process and should be evaluated for intervention. So, there's lots of places in our healthcare community where we could foster better outreach, better knowledge to get more folks access to the medicines. And this is before we even get to cost. Dr Monteith: Yeah, yeah. And obviously, there's some stigma as well.  Dr Geldmacher: That's right.  Dr Monteith: Really recognizing what the issues are and diving and asking those questions and funding research that asks those questions, as you mentioned, is really important. And then you have also a nice area where, you know, looking on the impact of treatments on caregiver-related outcomes, and of course ultimately want to keep patients out of nursing homes and prevent death. And so, can you talk a little bit about that? And, you know, mainly the caregiver burden.  Dr Geldmacher: So, my research in that area goes back a long way now. But I learned early in the course of therapy that many times the outcome that the family is noticing for symptomatic therapies is not a change in the patient's memory per se, but that there is less work involved in the caregiving. Less time is spent in direct caregiving roles. The patient may shadow less and because they have better independent cognition. I remember one family member once told me, the medicine you started is a godsend because now I can go to the bathroom by myself and he's not pounding on the door saying where are you, where are you. He's able to recall long enough that I'm in the bathroom that I have that moment of privacy. That was very meaningful to me to hear that. So. Dr Monteith: Cool. So why don't you just help us wrap this up and just give us, like, three main takeaway points that we should be getting out of your article? Dr Geldmacher: The three points that I would emphasize from my article is that the symptomatic therapies provide meaningful benefits and measurable, consistent, meaningful benefits. The second is that those benefits extend beyond things like cognitive test scores and into things like caregiver well-being and maintenance of independence in the home environment. And the third is that the disease-modifying therapies are an exciting opportunity to modify the pathology, but we still are learning about their cost effectiveness and their long-term benefit both to individuals and to society. But the only way we're going to learn that is by using them. And that was the experience that we gained from the symptomatic therapies that took use in the community for years before we really began to understand their true value. Dr Monteith: Thank you. That was excellent. And I put you on the spot, too.  Dr Geldmacher: No problem.  Dr Monteith: Again, today I've been interviewing Dr David Geldmacher, whose article on treatment of Alzheimer's disease appears in the most recent issue of Continuum on Dementia. Be sure to check out Continuum audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in depth and clinically relevant information important for neurology practitioners. Use this link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at contentpub.com/AudioCME. Thank you for listening to Continuum Audio.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/TEJ865. CME credit will be available until December 23, 2025.Exploring New Frontiers in Alzheimer's Disease: Early Detection, Emerging Mechanisms, and Therapeutic Advances In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Novo Nordisk Inc.Disclosure information is available at the beginning of the video presentation.

這集我們會談到： 1.墾丁陽傘事件在網紅揭露後，墾管處如何處理？？ 2.墾丁旅遊有哪些經常讓人詬病的地方？物價過高！！ 3.網路上流傳了什麼有關墾丁夜市物價的笑話？？ 4.Fana到花蓮遊玩，入住煙波飯店價格如何？？ 5.地震過後適合去花蓮玩？目前旅遊品質極高？？ 6.疫情期間的小人國，有何優質的旅遊體驗？？ 7.想當年，Joe&Anna大學時期的東部熱血之旅 8.墾丁國旅已死？該如何置之死地而後生？ 9.到墾丁玩不如到沖繩玩？小琉球比墾丁近？ 10.同樣設計旅遊活動，台灣業者比日本差在哪裡？ 【背景介紹】 墾丁海灘「陽傘亂象」惹議，網紅拍片揭穿墾丁陽傘爭議後引起群眾撻伐，墾丁國家公園管理處全面稽查並出動挖土機清除，不過，南灣沙灘整頓後不到一周時間陽傘之亂又故態復萌，讓人不禁感嘆先前的取締只是虛晃一招…..。 請贊助我一杯咖啡，感謝您的贊助，讓我們能走得更遠、更久

Streamy na 2padach są równie rzadkie, co najrzadsze Pokemony. Krążą o nich legendy, ale niewielu widziało je na oczy. Wśród nich były te poświęcone Pokemon Red, przygotowane przez Bacchiego pod koniec 2022 (linki znajdziecie pod opisem). Pół roku później nagrał on w ramach podcastu razem z Noksem swoje przemyślenia na temat Pokemon Legends: Arceus i Pokemon Scarlet and Violet, starając się porównać obie, zaskakująco różniące się od siebie gry. Niesprzyjające okoliczności sprawiły jednak, że odcinek nigdy się nie ukazał, co postanowiliśmy nadrobić teraz w ramach przedświątecznych porządków. Z tej okazji...Przeczytaj całość

Panelet går igjennom sesongens siste maratonløp og analyserer løpet. Vi ser også frem til Team Macody 10KM på kommende lørdag, der alle lyttere er invitert!

Panelet tar en siste fot i bakken før det braker løs i Fana på lørdag. Veien videre etter nyttår diskuteres. Eggen Mjøs avslører sin nye klubb. Ulike pacing-grupper avtales.

Panelet går gjennom sist ukes trening. Mathias avslører hemmeligheten rundt å holde seg frisk. Detaljene rundt Kvalø Classic 10 km spikres. Live-opptak fra lørdagens økt!

In this episode , we dive into the chilling world of the 2017 horror film "The Ritual" and its dark themes of ancient worship and sacrifice. Inspired by the movie's unsettling lore, we explore real-life stories of rituals and mysterious disappearances.   We uncover the shocking serial killings in Fana, Mali, and the eerie disappearance of Dennis Martin, weaving in tales of modern and historical rituals that blur the line between superstition and horror. To balance the darkness, we also delve into the bizarre true story of the infamous “Cocaine Bear” Chapters 00:00 Opening 00:35 Intro and Announcements 1:55 Ritual review: 1:55 7:07 Ancient Rituals 11:58 False accusations of sacrifice 12:51 Vikings 13:39 Modern sacrifice 14:34 Fana Serial Killer 18:15 Missing in the woods 19:00 Denis Martin 23:04 Final Fright - Cocaine Bear 24:24 Closing Resources https://en.natmus.dk/historical-knowledge/denmark/prehistoric-period-until-1050-ad/the-viking-age/religion-magic-death-and-rituals/the-viking-blot-sacrifices/#:~:text=It%20was%20always%20important%20for,fertility%20or%20luck%20in%20battle. https://nypost.com/2020/07/04/why-hundreds-of-people-vanish-into-the-american-wilderness/ https://nypost.com/2023/06/14/us-national-park-visitors-disappearing-without-a-trace/ https://www.britannica.com/topic/human-sacrifice https://www.oxfordbibliographies.com/display/document/obo-9780199791231/obo-9780199791231-0272.xml#:~:text=As for texts about burning,as punishment of the parents. https://www.jstor.org/stable/219450 https://muse.jhu.edu/book/27519/#:~:text=One example, the Ghana Asante,in order to guarantee victory. https://en.wikipedia.org/wiki/Dahomey#Religion https://biblereadingarcheology.com/2016/05/13/did-the-canaanites-sacrifice-their-children/ https://www.ox.ac.uk/news/2014-01-23-ancient-carthaginians-really-did-sacrifice-their-children https://www.ancient-egypt.org/from-a-to-z/h/human-sacrifice.html#:~:text=When examining human sacrifice, the,is therefore not discussed here. https://www.youregypttours.com/egypt-tours-blog/sacrifice-in-ancient-egypt https://en.wikipedia.org/wiki/Disappearance_of_Dennis_Martin#:~:text=Dennis Lloyd Martin (born June,(150 km2) area. https://www.wbir.com/article/news/special-reports/the-vanished/the-vanished-dennis-martin/51-dea1f82d-4bfa-470b-9a69-5b2c603c1510

Hedda Mae er artist, musiker og låtskriver. Hun har et veldig todelt forhold til anger, og angrer på veldig lite generelt i livet, men på grunn av at hun er dårlig til å ta valg, så angrer hun på veldig mange småting. Vi snakker bl.a. om debutalbumet «Channel Mae», og den konseptuelle utviklingen av det i et slags radioformat, som er mye inspirert av Grand Theft Auto og amerikanske radioreklamer, at hun er forberedt på en krasjlanding etter en omfattene releaseuke, og burde bestilt seg en ferietur, men tar til takke med hytta, å ikke være spesielt glad i å slippe musikk, og at det er låtskrivingen og livespillingen som er aller morsomst, oppveksten i Bergen, og at hun alltid holdt på Oslodialekten sin, og kunne føle seg litt utenfor i det rike merkekledde miljøet på Fana, å ikke like søndagsmiddager, og generelt være ganske dårlig til å lage mat, fordi hun glemmer at hun gjør det, å bestille det samme som minst én annen rundt bordet på restaurant, for å ikke angre og en god del om at selv om Bergen har eierskap til dårlig vær, så er det aldri så kaldt som i Trøndelag og kjærligheten til mukbang- og dyrevideoer og at hun blir sur av teite tekster i musikk.Programleder: Sivert MoeSupport this show http://supporter.acast.com/anger. Hosted on Acast. See acast.com/privacy for more information.

**REPOST** Our Carrier Connections program features a different X-linked condition each month with the goal to increase awareness of X-linked conditions and how they impact the lives of women and girls. This month, we are featuring ornithine transcarbamylase (OTC) deficiency is an X-linked genetic disorder marked by a complete or partial lack of the enzyme ornithine transcarbamylase. This enzyme is critical to the urea cycle as it is tasked with converting ammonia, a byproduct from the breakdown of excess protein subunits in the body, to urea so that the body can excrete it through the urine. In individuals with OTC deficiency, this enzyme does not function properly, resulting in the accumulation of ammonia in the bloodstream. The presence of excess ammonia in the blood causes complications in the nervous system, resulting in a range of severe to mild symptoms. OTC deficiency can become evident at any age, but has the most extreme effects when it occurs in infants. Symptoms in females are widely variable, with some individuals showcasing more severe clinical manifestations than others, and some not having any reported symptoms. For example, while some females only report chronic headaches following protein consumption, other individuals have been found to experience acute liver failure, hyperammonemia, and other symptoms typically seen in affected males. Additionally, some females report worsening symptoms during pregnancy and require close monitoring of protein levels by a medical team to ensure a safe delivery. Even so, females are at a heightened risk of hyperammonemic crisis during pregnancy and should consult their physician before getting pregnant. OTC deficiency is an X-linked genetic disorder marked by a complete or partial lack of the enzyme ornithine transcarbamylase. This results in the accumulation of ammonia in the bloodstream and causes complications in the nervous system, resulting in a range of severe to mild symptoms. Approximately 20% of OTC females experience symptoms. Some females do not express excess ammonia levels until pregnancy. Females who do develop symptoms in childhood often experience headaches after protein ingestion. A study determined that girls with OTC deficiency may exhibit episodes of hyperammonemic encephalopathy, or ammonia buildup in the brain, and cognitive decline. Today, we are joined by Andrea Gropman, M.D., FAAP, FACMG, FANA. Dr. Gropman is the Director of Neurometabolic Translational Research Center for Experimental Neurotherapeutics St. Jude Children's Research Hospital. She is also is the principal investigator of the Urea Cycle Disorders Consortium (UCDC) and the UCDC imaging consortium and the deputy clinical director of the Mito EpiGen Program. Her research interest focuses on establishing biomarkers of neurological injury in patients with inborn errors of metabolism, such as urea cycle disorders and mitochondrial disorders, using specialized neuroimaging modalities and cell markers. Carrier Connections is sponsored by Kyowa Kirin and Amgen. For more information about our organization, check out ⁠⁠⁠⁠⁠⁠rememberthegirls.org⁠⁠⁠⁠⁠⁠. OTC resources: ⁠https://checkammonia.com/⁠ ⁠https://www.ucdincommon.com/⁠ ⁠https://nucdf.org/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NMQ865. CME credit will be available until September 16, 2025.From Early Detection to Disease Modification: Personalized Approaches to Biomarker Testing and Therapeutic Management of Alzheimer's Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant by Eisai Inc.Disclosure information is available at the beginning of the video presentation.

Na saunoa le sui tauva o le Democratic Party mo le tofi sui peresitene, Tim Walz, ina ua toe tupu mai se osofa'iga i se a'oga i Amerika ua tafanaina ma maliliu ai tamaiti a'oga, o ia ua iso i le tupu pea o nei osofa'iga, ma lau mai le manatua i talosaga o e ua maliliu ma aiga. Ua tatau ona faia se faai'uga faaletulafono i fana.

Fana Hues started her career as a musician at two years old. "Moth" shows her expertise, blending serious song craft into pop R&B bangers. We talked to her on the balcony of The Ryman before her performance at the Mother Church.

E 12 tausaga le matua o se tamaititi na fanaina ma maliu ai i se nu'u i Savai'i i le faai'uga o le vaiaso na te'a nei.

In the latest Faculty Factory Podcast episode, Ludy Shih, MD, MMSc, FAAN, FANA, returns to share invaluable insights on running effective meetings. In this interview, Dr. Shih emphasizes the importance of preparation, structured agendas, and follow-up. She also touches on the challenges of engaging different personality types in meetings and offers strategies to ensure all voices are heard. Dr. Shih is a neurologist and associate professor of neurology with Beth Israel Deaconess Medical Center at Harvard Medical School. She has been generous enough to allow us to post her entire slide deck on this topic, which you can download here: https://facultyfactory.org/wp-content/uploads/2024/05/Meeting_Faculty_factory_05_09.pdf Within the slide deck, there are hyperlinks pointing to various articles that Dr. Shih used as references in today's interview. Learn More You can revisit her first episode with us, “Navigating a Transition from Academia to Industry and Back”, here: https://facultyfactory.org/ludy-shih/ Email Dr. Shih with questions here: lshih@bidmc.harvard.edu Connect on LinkedIn: https://www.linkedin.com/in/ludy-shih-a7b53212/ Follow on Twitter/X: https://x.com/ludyshihmd Programming Note We love to learn from faculty members around the world. If you or someone you'd like to nominate wants to be a guest on our show, reach out to us via the Contact Us page on FacultyFactory.org or email the show directly here: kskarupski@jhmi.edu. You can also find more Faculty Factory podcast episodes here: https://facultyfactory.org/podcast/

Ua lata i le 30 tausaga talu ona faia le osofa'iga i Port Arthur i Tasmania lea na maliliu ai tagata ina ua fanaina e seisi ma faatulagaina ai tulafono e aiaia ai le umia e tagata sivili o fana i Ausetalia.

Today our magic jeep visits Chief Zewdu and his sister Fana, who live deep in the savanna with a group of baboons. Despite being the leader, Zewdu notices the other monkeys bossing each other around! Join us on our adventure to find out how Zewdu and Fana bring order to this rowdy bunch!